ATE308344T1 - Auf peptiden basierende tragvorrichtungen für sternzellen - Google Patents

Auf peptiden basierende tragvorrichtungen für sternzellen

Info

Publication number
ATE308344T1
ATE308344T1 AT98949252T AT98949252T ATE308344T1 AT E308344 T1 ATE308344 T1 AT E308344T1 AT 98949252 T AT98949252 T AT 98949252T AT 98949252 T AT98949252 T AT 98949252T AT E308344 T1 ATE308344 T1 AT E308344T1
Authority
AT
Austria
Prior art keywords
receptor
disease
peptide
hsc
compound
Prior art date
Application number
AT98949252T
Other languages
English (en)
Inventor
Klaas Poelstra
Eleonora Beljaars
Dirk Klaas Fokke Meijer
Detlef Bruno Igor Schuppan
Original Assignee
Stichting Tech Wetenschapp
Univ Groningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Tech Wetenschapp, Univ Groningen filed Critical Stichting Tech Wetenschapp
Application granted granted Critical
Publication of ATE308344T1 publication Critical patent/ATE308344T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98949252T 1998-10-08 1998-10-08 Auf peptiden basierende tragvorrichtungen für sternzellen ATE308344T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL1998/000579 WO2000023113A1 (en) 1998-10-08 1998-10-08 Peptide-based carrier devices for stellate cells

Publications (1)

Publication Number Publication Date
ATE308344T1 true ATE308344T1 (de) 2005-11-15

Family

ID=19866457

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98949252T ATE308344T1 (de) 1998-10-08 1998-10-08 Auf peptiden basierende tragvorrichtungen für sternzellen

Country Status (9)

Country Link
US (3) US6844319B1 (de)
EP (1) EP1117443B1 (de)
JP (1) JP2002532384A (de)
AT (1) ATE308344T1 (de)
AU (2) AU770340B2 (de)
CA (1) CA2345932C (de)
DE (1) DE69832204T2 (de)
HK (1) HK1039450B (de)
WO (1) WO2000023113A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264949B1 (en) 1998-09-29 2001-07-24 Mount Sinai School Of Medicine Of New York University Noninvasive agents for diagnosis and prognosis of the progression of fibrosis
WO2003035083A1 (de) * 2001-10-26 2003-05-01 Ribopharma Ag Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
US7160577B2 (en) * 2002-05-02 2007-01-09 Micron Technology, Inc. Methods for atomic-layer deposition of aluminum oxides in integrated circuits
US7589029B2 (en) * 2002-05-02 2009-09-15 Micron Technology, Inc. Atomic layer deposition and conversion
EP1910520A4 (de) * 2005-06-09 2009-05-27 Agency Science Tech & Res Für hepatische stellatzellen spezifischer promotor und verwendungen davon
US20070299029A1 (en) * 2005-06-09 2007-12-27 Agency For Science, Technology And Research Hepatic stellate cell specific promoter and uses thereof
US7927948B2 (en) 2005-07-20 2011-04-19 Micron Technology, Inc. Devices with nanocrystals and methods of formation
US7575978B2 (en) 2005-08-04 2009-08-18 Micron Technology, Inc. Method for making conductive nanoparticle charge storage element
US7989290B2 (en) * 2005-08-04 2011-08-02 Micron Technology, Inc. Methods for forming rhodium-based charge traps and apparatus including rhodium-based charge traps
WO2007038568A1 (en) * 2005-09-27 2007-04-05 Teotten Diagnostics, Inc. Methods for detection of fungal disease
GB0524987D0 (en) * 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
US8367506B2 (en) * 2007-06-04 2013-02-05 Micron Technology, Inc. High-k dielectrics with gold nano-particles
EP2448600B1 (de) * 2009-07-03 2016-03-30 INSERM - Institut National de la Santé et de la Recherche Médicale Auf den kationunabhängigen mannose 6-phosphat-rezeptor gerichtete verbindungen
EP2343081A1 (de) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon-Analoga
WO2012173994A2 (en) 2011-06-15 2012-12-20 Dicerna Pharmaceuticals, Inc. Phase changing formulations of nucleic acid payloads
JP5378469B2 (ja) 2011-08-11 2013-12-25 学校法人 日本歯科大学 医療用薬剤
WO2020132100A1 (en) 2018-12-19 2020-06-25 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules for lysosomal targeting and related compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0906015A4 (de) 1996-06-06 2004-05-12 Neorx Corp Mittel zur unterdrückung von rückhalteprozessen in der leber
EP0844252A3 (de) 1996-11-15 1998-07-08 Remacle, José Zyklische Peptide mit einer zur anschliessenden chemischen Kupplung entworfenen Zweiggruppe und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
EP1117443B1 (de) 2005-11-02
US20080267877A1 (en) 2008-10-30
WO2000023113A1 (en) 2000-04-27
CA2345932C (en) 2010-07-13
AU9560998A (en) 2000-05-08
DE69832204T2 (de) 2006-07-27
US6844319B1 (en) 2005-01-18
AU770340B2 (en) 2004-02-19
HK1039450A1 (en) 2002-04-26
US20050227916A1 (en) 2005-10-13
EP1117443A1 (de) 2001-07-25
US7348313B2 (en) 2008-03-25
JP2002532384A (ja) 2002-10-02
HK1039450B (zh) 2006-02-03
AU2005203633B2 (en) 2007-09-06
AU2005203633A1 (en) 2005-09-08
DE69832204D1 (de) 2005-12-08
CA2345932A1 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
ATE308344T1 (de) Auf peptiden basierende tragvorrichtungen für sternzellen
Brown et al. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections
EA201170337A1 (ru) Стабильная твердая композиция полипептидного агониста gc-c рецептора, приемлемая для перорального введения
EA200000629A1 (ru) Стабилизированные растворы терипаратида
Velkov et al. Rediscovering the octapeptins
Yoshikawa et al. Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: New insight into CXCR4–FC131 interactions
ZA200501715B (en) Solution for ungual application
MY129417A (en) Zinc-free and low-zinc insulin preparations having improved stability
ES2103857T3 (es) Peptidos ciclicos y su uso.
EA200901108A1 (ru) Соагонисты глюкагоновых/glp-1-рецепторов
BRPI0819319B8 (pt) análogos de aminoglicosídeo antibacteriano
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
Tamamura et al. Structure–activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds
DE69927582D1 (de) Neue analoga von 16-hydroxyeicosatetraensäure
CA2182795A1 (en) Superactive vip antagonists
EP1571155A4 (de) Peptide und medizinische zusammensetzungen mit denselben
RU2015108678A (ru) Составы ангиотензина для перорального применения
Saitoh et al. Restricted intestinal absorption of some β-lactam antibiotics by an energy-dependent efflux system in rat intestine
Tamamura et al. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs
AR030247A1 (es) Arileteno-sulfonamidas, composiciones farmaceuticas , procedimiento para su produccion y el uso de las mismas para la produccion de composiciones farmaceuticas
ITRM20020277A1 (it) Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.
WO2001034640A3 (de) Humanes zirkulierendes virus inhibierendes peptid (virip) und seine verwendung
AR022537A1 (es) Composiciones farmaceuticas que comprenden sales de peptidos farmaceuticamente activos de liberacion sostenida; y metodo para preparar dichas composiciones
Rivier et al. Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides
MX2007014803A (es) Composiciones que penetran el nucleo celular.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties